Research programme: anticancer monoclonal antibodies - AbbVie/Caprion Proteomics

Drug Profile

Research programme: anticancer monoclonal antibodies - AbbVie/Caprion Proteomics

Alternative Names: Lung cancer therapeutics research programme - AbbVie/Caprion

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Caprion Pharmaceuticals
  • Developer AbbVie; Caprion Proteomics
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Canada (Parenteral)
  • 23 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 23 Sep 2011 This research programme appears to still be active
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top